Publications

Authors:

Onorati, F; Quintana, E; El-Dean, Z; Perrotti, A; Sponga, S; Ruggieri, Vg; Rinaldi, M; Milano, Ad; Santini, F; Chocron, S; Livi, U; Salizzoni, S; Loizzo, T; Salsano, A; Di Cesare, A; Faggian, G; Castella, M; Nicolini, F

Title:

Aortic Valve Replacement for Aortic Stenosis in Low-, Intermediate-, and High-Risk Patients: Preliminary Results From a Prospective Multicenter Registry

Year:

2020

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

No

Name of journal:

Journal of Cardiothoracic and Vascular Anesthesia

ISSN of journal:

1053-0770

N° Volume:

34

Number or Folder:

8

Page numbers:

2091-2099

Keyword:

aortic valve replacement; transcatheter aortic valve implantation; aortic stenosis; surgical outcome

Short description of contents:

Objective: To evaluate current results of surgical aortic valve replacement (SAVR) +/- coronary artery bypass grafting surgery.Design: Independent, multicenter, prospective registry.Setting: Tertiary university hospitals.Participants: The study comprised 1,192 consecutive patients, stratified as low-, intermediate-, and high-risk according to EuroSCORE II (<4, 4-9, >9, respectively).Interventions: SAVR +/- coronary artery bypass grafting surgery.Measurements and Main Results: Thirty-day mortality and major morbidity, 2-year actuarial survival and freedom from stroke, and independent predictors of mortality in each risk category were assessed. These data were considered in light of published randomized controlled trials. Thirty-day mortality was 1.0%, 3.0% and 2.1% in the low-, intermediate-, and high-risk patients, with a 2-year actuarial survival of 98.6%, 93.8%, and 94.0%, respectively. Preoperative atrial fibrillation (odds ratio [OR] 8.3), minithoracotomy access (OR 5.8), postoperative dialysis (OR 3.4), type V acute myocardial infarction (OR 20.4), and moderate aortic regurgitation (OR 28.8) predicted 30-day mortality in the low-risk group. Preoperative dialysis (OR 18.3), critical state (OR 36.7), postoperative transfusions of plasma (OR 1.9 per unit transfused), and de-novo dialysis (OR 6.2) predicted 30-day mortality in the intermediate-risk group. Prior cardiac surgery (OR 18.1), postoperative extracorporeal membrane oxygenation (OR 9.8), and gastrointestinal complications (OR 17.2) predicted 30-day mortality in the high-risk group. Although baseline differences existed, low-risk patients demonstrated low 30-day mortality and 30-day to 12-month stroke in light of the PARTNER 3 and EVOLUT Low Risk trial results. Intermediate-risk patients demonstrated low 30-day to 2-year mortality, when the PARTNER 2 trial was considered, and low 30-day to 2-year stroke, when the PARTNER 2 and SURTAVI trials were considered. High-risk patients showed low 30-day to 2-year mortality in light of the results of the PARTNER 1 and CoreValve US trials.Conclusions: SAVR is still a safe and effective surgery for aortic stenosis regardless of risk category. (C) 2020 Elsevier Inc. All rights reserved.

Product ID:

116360

Handle IRIS:

11562/1025512

Last Modified:

November 17, 2022

Bibliographic citation:

Onorati, F; Quintana, E; El-Dean, Z; Perrotti, A; Sponga, S; Ruggieri, Vg; Rinaldi, M; Milano, Ad; Santini, F; Chocron, S; Livi, U; Salizzoni, S; Loizzo, T; Salsano, A; Di Cesare, A; Faggian, G; Castella, M; Nicolini, F, Aortic Valve Replacement for Aortic Stenosis in Low-, Intermediate-, and High-Risk Patients: Preliminary Results From a Prospective Multicenter Registry «Journal of Cardiothoracic and Vascular Anesthesia» , vol. 34 , n. 8 , 2020 , pp. 2091-2099

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo